Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. - Wikidata - awgldk - TriplyDB

Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety.

Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety.

http://www.wikidata.org/entity/Q42163306

about

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis Inhaled anti-infective chemotherapy for respiratory tract infections: successes, challenges and the road ahead Tobramycin Inhalation Powder (TIP): An Efficient Treatment Strategy for the Management of Chronic Pseudomonas Aeruginosa Infection in Cystic Fibrosis Activity and interactions of liposomal antibiotics in presence of polyanions and sputum of patients with cystic fibrosis Tolerability and Pharmacokinetic Evaluation of Inhaled Dry Powder Tobramycin Free Base in Non-Cystic Fibrosis Bronchiectasis Patients Clinical experimentation with aerosol antibiotics: current and future methods of administration.Measuring and improving respiratory outcomes in cystic fibrosis lung disease: opportunities and challenges to therapy Inhaled Antibiotic Therapy in Chronic Respiratory Diseases.Antibiotic management of lung infections in cystic fibrosis. I. The microbiome, methicillin-resistant Staphylococcus aureus, gram-negative bacteria, and multiple infections Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial.Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial.Pharmacokinetics and pharmacodynamics of aerosolized antibacterial agents in chronically infected cystic fibrosis patients.Efficacy and safety of inhaled calcium lactate PUR118 in the ozone challenge model--a clinical trial.Ciprofloxacin DPI: a randomised, placebo-controlled, phase IIb efficacy and safety study on cystic fibrosis.Update in cystic fibrosis 2007.High treatment burden in adults with cystic fibrosis: challenges to disease self-management.Treatment satisfaction in cystic fibrosis: early patient experience with tobramycin inhalation powder Synergistic antibiotic combination powders of colistin and rifampicin provide high aerosolization efficiency and moisture protection.Delivery of antibiotics to the respiratory tract: an update.Update on antibiotics for infection control in cystic fibrosis.Consensus summary of aerosolized antimicrobial agents: application of guideline criteria. Insights from the Society of Infectious Diseases Pharmacists.Aztreonam lysine: a novel inhalational antibiotic for cystic fibrosis.Challenges and advances in the development of inhalable drug formulations for cystic fibrosis lung disease.Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere™ technology.Clinical perspective on aztreonam lysine for inhalation in patients with cystic fibrosis.Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis.Tobramycin administered by the TOBI(®) Podhaler(®) for persons with cystic fibrosis: a review.Tobramycin inhalation powder: a review of its use in the treatment of chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.Lactose engineering for better performance in dry powder inhalers.Emerging drugs for cystic fibrosis.The PulmoSphere™ platform for pulmonary drug delivery.Enhancing adherence to inhaled therapies in cystic fibrosis.The role of particle physico-chemical properties in pulmonary drug delivery for tuberculosis therapy.Use of inhaled tobramycin in cystic fibrosis.Tobramycin inhalation powder: an efficient and efficacious therapy for the treatment of Pseudomonas aeruginosa infection in cystic fibrosis.Clinical pharmacokinetics of inhaled antimicrobials.Long-term safety and efficacy of tobramycin in the management of cystic fibrosis.Long-term safety of tobramycin inhalation powder in patients with cystic fibrosis: phase IV (ETOILES) study.

P2860

Q24188054-605C7FF6-A7A7-4A66-AB05-7CC59A334C7C Q24202283-E72789E0-FAAF-4D27-86D4-639312D4C8A4 Q26822988-DE012E43-FF27-4308-9CAC-7CB0D9B58576 Q26829604-749862E1-C2F3-46EE-BBEB-38E5D0BD182E Q28475562-D5BD7B95-43A7-4053-A0A2-E0E9D7EC592F Q28550641-15FE62F0-2AE7-46B8-8EE2-994A72829295 Q30448377-54A9E525-841E-4D12-B294-1E4A4E2DDC2D Q33697276-376656EC-3B22-47D5-A6EB-BEF9C3DF60B0 Q33755342-8A7CCE9A-55D8-466A-A6AA-9041B8510E34 Q33786154-950CFD56-186A-4E33-B570-A0C2C50B6058 Q33861117-56ED2EE9-8A99-4D56-A5A4-698DF4BB7E4F Q33862073-C48DC040-2CE6-4F58-9D42-77A56A2899FB Q33957168-58C6E240-B8C1-4585-BF93-D20621144B4D Q34297656-CA745152-D6B7-4525-992D-11AA108952A2 Q35743384-6204E9A2-359B-4D80-B0BF-966E111A69E4 Q36374382-43550832-6792-4DCD-A572-84B922493F78 Q37156059-E65F2A14-778E-4CA2-82BE-6475BB16BFA2 Q37187487-7EC34446-9CC5-4548-A653-D74508299B0D Q37381499-0FF704E3-BEF0-4CD1-98FA-DC9FA71A33C2 Q37469403-6C134120-1FAF-4F8E-B866-35811D03ADB5 Q37564542-594F2B89-8AF3-49C6-955F-E833A254DCC5 Q37608274-F9E6A145-6C35-4E4E-81B2-B9BB4D900849 Q37760514-58E1D98A-A981-44AA-A95F-C668869C7976 Q37775620-CB1C332B-32C7-4220-8948-0D6555CC604D Q37849777-EC7E2911-EEE0-48A9-A368-A5137A24C52B Q37851986-D9CC79E6-D860-4CA4-954C-2EDF4F5220FD Q37892898-F12EE396-B44D-454F-B087-BF904B866830 Q37940005-387FFD64-0420-4808-AB44-BE2601F78805 Q38037076-93C24655-452E-461F-AEF6-C7E9408887EF Q38160206-3FAFC0E7-FC1C-48F4-8AC2-A427F52029BF Q38169161-153EEB7A-ADC7-40AE-9E9E-34A1A8D3DB9A Q38183476-ED41D0D0-86A2-4615-A978-7ACE946868D3 Q38193170-CCF6EFB3-F3A1-44CA-9B45-60EE1D2D351A Q38193291-110E12F2-598F-47D3-BF26-AF5F464B5EE7 Q38236719-7F2ADCBB-7977-40C0-BFF9-58899BE784EF Q38332222-8E3C894B-BBB6-43D0-8D6B-B713202FA1D8 Q38358856-7297F4E0-A645-4FEA-B367-734279FAC51A Q38367260-BE21A19C-3936-448B-9ACA-E840AACE69B8 Q38384994-5F824C99-128B-4163-8FB3-DEFCE2903DED Q38386414-1297914C-A007-4D57-81CB-29926179BB13

P2860

Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety.

http://www.wikidata.org/entity/Q42163306

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Novel tobramycin inhalation po ...... : pharmacokinetics and safety.

@en

Novel tobramycin inhalation po ...... : pharmacokinetics and safety.

@nl

type

label

Novel tobramycin inhalation po ...... : pharmacokinetics and safety.

@en

Novel tobramycin inhalation po ...... : pharmacokinetics and safety.

@nl

prefLabel

Novel tobramycin inhalation po ...... : pharmacokinetics and safety.

@en

Novel tobramycin inhalation po ...... : pharmacokinetics and safety.

@nl

P1433

Q42163306-11C3D556-BC07-4AC2-B9CB-E94A97E4DE2B

P1476

Q42163306-50937F51-87A2-4B3C-9399-004B0C745009

P2093

Q42163306-3770A589-1F2A-4279-BB5E-769717EAD543

Q42163306-636653B8-88A4-444C-BD9F-2E2213F96B5F

Q42163306-8B658FCD-BFF4-4C14-8A57-49DE18C75FC9

Q42163306-CDEC9367-1569-4D16-8396-49D3F9BA42A6

Q42163306-F799904E-4B5C-4683-A165-2E4354FBBD70

P2860

Q42163306-4DE592C7-D6D3-425D-9DA3-A3F7467FA56E

Q42163306-7EFD2CE7-8078-4981-BDDF-E68327066046

Q42163306-E047A8CB-4C8C-4D96-9CF9-651D45375643

P304

Q42163306-5943DA60-F821-46CB-BE28-7970A4C4A916

P31

Q42163306-DECDADAD-0A28-4AA2-9E77-181D30B0A195

P356

Q42163306-50C45942-D928-4778-9D0F-8A4143604E66

P433

Q42163306-266F77B9-9F3D-4D58-9B0B-A97CF140A7E8

P478

Q42163306-7599CADF-63A3-4889-A2E4-6FCB921411FA

P577

Q42163306-3303B88E-4F2E-4113-996A-F8839F5A0C23

P5875

Q42163306-09748D34-697F-474C-B29F-ED7278FC1F6D

P698

Q42163306-D784D8F8-EC2F-4644-BC5C-49C433C376DA

P921

Q42163306-BE4F9323-073E-4771-85AA-7FAC27306602

P356

P1433

Pediatric Pulmonology

P1476

Novel tobramycin inhalation po ...... : pharmacokinetics and safety.

@en

P2093

Carol Conrad

http://www.w3.org/2001/XMLSchema#string

David E Geller

http://www.w3.org/2001/XMLSchema#string

Jeffrey Smith

http://www.w3.org/2001/XMLSchema#string

Michael W Konstan

http://www.w3.org/2001/XMLSchema#string

Sarah B Noonberg

http://www.w3.org/2001/XMLSchema#string

P2860

Standardization of Spirometry, 1994 Update. American Thoracic Society

Lower bronchodilator responsiveness in Puerto Rican than in Mexican subjects with asthma.

The role of nebulized antibiotics in treating serious respiratory infections.

P304

307-313

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PPUL.20594

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

42

http://www.w3.org/2001/XMLSchema#string

P577

2007-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6455453

http://www.w3.org/2001/XMLSchema#string

P698

17352404

http://www.w3.org/2001/XMLSchema#string

P921

cystic fibrosis